tradingkey.logo

Citius Oncology Announces Preliminary Topline Phase 1 Data From Study Of Lymphir™ (E7777) Dosing Prior To Commercial Car‑T Therapy In High‑Risk Diffuse Large B‑Cell Lymphoma

ReutersMar 4, 2026 2:20 PM

- Citius Oncology Inc CTOR.O:

  • CITIUS ONCOLOGY ANNOUNCES PRELIMINARY TOPLINE PHASE 1 DATA FROM STUDY OF LYMPHIR™ (E7777) DOSING PRIOR TO COMMERCIAL CAR‑T THERAPY IN HIGH‑RISK DIFFUSE LARGE B‑CELL LYMPHOMA

  • CITIUS ONCOLOGY INC - LYMPHIR WELL-TOLERATED WITH NO DOSE-LIMITING TOXICITIES OBSERVED IN PHASE 1 STUDY

  • CITIUS ONCOLOGY INC - PHASE 1 STUDY SHOWS 86% OVERALL RESPONSE RATE, 57% COMPLETE RESPONSE, 29% PARTIAL RESPONSE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI